Unexplained pancytopenia in acute myeloid leukemia treatment

Clinical Case Reports
Daniel EzekwudoPhilip Kuriakose

Abstract

Certain histopathological findings have been described in acute myeloid leukemia (AML) patients during treatment that define the hematologic outcomes. Such entities as bone marrow necrosis and hemophagocytic lymphohistiocytosis have been reported. These often result in severe pancytopenia.

References


❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

[Rinshō ketsueki] The Japanese journal of clinical hematology
Yutaka Imamura
The Pediatric Infectious Disease Journal
M E Lim, K S Kim
Nihon rinsho. Japanese journal of clinical medicine
Yutaka Imamura
© 2022 Meta ULC. All rights reserved